Olga Salamero

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Journal: Leukemia & lymphoma
Published: July 26, 2026

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Journal: American journal of hematology
Published: June 23, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica
Published: March 10, 2026

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Journal: American journal of hematology
Published: February 05, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

Journal: Haematologica
Published: June 26, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy
Published: May 19, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy
Published: May 19, 2025

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Journal: European journal of haematology
Published: November 20, 2024

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Journal: Blood cancer journal
Published: October 17, 2024

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Journal: The Lancet. Oncology
Published: May 07, 2024
Showing 1-12 of 66

Last Updated: 09/26/2026